Jump to Main Contents
先端医療開発センター

Home > Mitsuyoshi Yoshimoto, PhD

Mitsuyoshi Yoshimoto, PhD

吉本 光喜

My research focuses are the synthesis, development, and validation of radiopharmaceuticals. Especially, my recent interest is the development of targeted radionuclide therapy for pancreatic cancer, brain tumor, etc.

Official title

  • Division of Functional Imaging, Senior Scientist
  • National Institute of Radiological Sciences, Visiting Researcher

Area of Research

  • Molecular Imaging
  • Radiopharmaceutical

Keywords

  • Molecular imaging
  • Early diagnosis
  • Prediction of therapeutic efficacy
  • Radionuclide therapy

Current main research theme 

  • Development of molecular imaging to predict therapeutic efficacy
  • Development of radiopharmaceuticals for tumor imaging and radionuclide therapy

Collaborative research themes

  • Development of radiopharmaceuticals for tumor imaging and radionuclide therapy

Email

yoshim●ncc.go.jp(Replace ● to @)

Brief History

  • 1995, B.S. Osaka University of Pharmaceutical Sciences
  • 1997, M.S. Osaka University of Pharmaceutical Sciences
  • 2001, Ph.D. Faculty of Medical Sciences, Fukui Medical University
  • 2001-2002, Post-doctoral Fellow, Foundation for Biomedical Research and Innovation
  • 2002-2009, Assistant Professor, Department of Quantum Medical Technology, Division of Health Sciences, Graduate School of Medical Sciences, Kanazawa University
  • 2009-Present, Senior Scientist, National Cancer Center
  • 2011-Present, Senior Scientist, National Cancer Center Hospital East, Division of Functional Imaging

Major affiliated societies

  • Japanese Cancer Association
  • Japanese Society of Nuclear Medicine
  • Japanese Society of Molecular Imaging
  • Pharmaceutical Society of Japan
  • Society of Nuclear Medicine and Molecular Imaging

Publications

  1. Yoshii Y, Furukawa T, Matsumoto H, Yoshimoto M, Kiyono Y, Zhang MR, Fujibayashi Y, Saga T. 64Cu-ATSM therapy targets regions with activated DNA repair and enrichment of CD133+ cells in an HT-29 tumor model: Sensitization with a nucleic acid antimetabolite. Cancer Lett., 376(1):74-82, 2016.
  2. Yoshimoto M, Kurihara H, Fujii H. Theragnostic imaging using radiolabeled antibodies and tyrosine kinase inhibitors. ScientificWorldJournal, 2015:842101,2015.
  3. Tani H, Kurihara H, Hiroi K, Honda N, Yoshimoto M, Kono Y, Murakami R, Kumita S, Arai Y, Itami J. Correlation of 18F-BPA and 18F-FDG uptake in head and neck cancers. Radiother. Oncol., 113(2):193-7, 2014.
  4. Yoshimoto M, Hirata M, Kanai Y, Naka S, Nishii R, Kagawa S, Kawai K, Ohmomo Y. Monitoring of gefitinib sensitivity with radioiodinated PHY based on EGFR expression. Biol. Pharm. Bull., 37(3):355-60, 2014.
  5. Yoshimoto M, Hayakawa T, Mutoh M, Imai T, Tsuda K, Kimura S, Umeda IO, Fujii H, Wakabayashi K. In vivo SPECT imaging using 111In-DOTA-c(RGDfK) to detect early pancreatic cancer in a hamster pancreatic carcinogenesis model. J. Nucl. Med., 53(5):765-71, 2012.

Visit PubMed for a listing of publications